Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Novartis' Phase 3 V MONO Study For Twice-yearly Leqvio (Inclisiran) Met Its Primary Endpoints Showing Leqvio Monotherapy Lowered Low-density Lipoprotein Cholesterol Versus Placebo And Ezetimibe In Patients Who Were At Low Or Moderate Risk Of Developing Atherosclerotic Cardiovascular Disease And Not Receiving Lipid-lowering Therapy

Author: Benzinga Newsdesk | August 28, 2024 06:13am

Posted In: NVS